Venetoclax, Obinutuzumab — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-11 (month) in 4mo
ESTIMATED |
READOUT
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax
Phase 2 · Chronic Lymphocytic Leukemia (CLL) |
ABBV AbbVie Inc. | Venetoclax, Obinutuzumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|